drugset / Trial / NCT07294534
A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is being conducted to evaluate the clinical efficacy of HLX87 in combination with HLX22 or pertuzumab vs. TCbHP in the neoadjuvant therapy of HER2-positive early or locally advanced breast cancer.
Timeline
- Start
- 2026-01-27
- Primary completion
- 2028-09-30
- Completion
- 2030-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Carboplatin | Small molecule | — | — |
| Comparator | Docetaxel | Small molecule | — | — |
| Subject | HLX22 | Monoclonal antibody | — | — |
| Subject | HLX87 | Other / unclassified | — | — |
| Subject | Pertuzumab | Monoclonal antibody | — | — |
| Comparator | Trastuzumab | Monoclonal antibody | — | — |